MSA
JAZZ icon

Mason Street Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

Mason Street Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-29,755
Closed -$4.91M – 617
2020
Q4 		$4.91M Buy
29,755
+72
+0.2% +$10.7K 0.08% 220
2020
Q3 		$4.23M Buy
+29,683
New +$3.68M 0.08% 220

Other funds holding JAZZ

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Mason Street Advisors's JAZZ Position: Q1 2021 in Review

Mason Street Advisors sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2021, closing a stake of 29,755 shares — an estimated $4.91M sold.

Mason Street Advisors first reported a position in JAZZ in Q3 2020 and held it in 2 quarters. The position peaked at $4.91M in Q4 2020. 441 funds tracked by Wall St. Rank hold JAZZ as of Q1 2021.

  • Mason Street Advisors reported no remaining Jazz Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Mason Street Advisors sold 29,755 Jazz Pharmaceuticals shares in Q1 2021, an estimated $4.91M.
  • Mason Street Advisors first reported a position in Jazz Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Mason Street Advisors's Jazz Pharmaceuticals position peaked at $4.91M in Q4 2020.
  • 441 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2021.

Based on Mason Street Advisors's 13F filing for Q1 2021, filed 14 May 2021.